G1 THERAPEUTICS, INC. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 34 rows, 34 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-05-22: Reporting owner Eshelman Ventures, LLC; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
- 2017-05-22: Reporting owner Eshelman Ventures, LLC; Form 4; Security Series C Preferred Stock; Transaction C Conversion of derivative security.
- 2017-05-22: Reporting owner Reed Douglas MD | LEE KENNETH B JR | Crumpler John | Hatteras Venture Advisors IV SBIC, LLC | Thorp Clay | Hatteras Venture Partners IV SBIC, LP | INGRAM ROBERT ALEXANDER; Form 4; Security Series 1 Preferred Stock; Transaction C Conversion of derivative security.
- 2017-05-22: Reporting owner Reed Douglas MD | LEE KENNETH B JR | Crumpler John | Hatteras Venture Advisors IV SBIC, LLC | Thorp Clay | Hatteras Venture Partners IV SBIC, LP | INGRAM ROBERT ALEXANDER; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-05-22 | Eshelman Ventures, LLC 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −6,893,224 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | Eshelman Ventures, LLC 10% Owner | 4 | Series C Preferred Stock Derivative · Direct | C Conversion of derivative security | −2,524,233 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | Reed Douglas MD | LEE KENNETH B JR | Crumpler John | Hatteras Venture Advisors IV SBIC, LLC | Thorp Clay | Hatteras Venture Partners IV SBIC, LP | INGRAM ROBERT ALEXANDER 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series 1 Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −1,318,681 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | Reed Douglas MD | LEE KENNETH B JR | Crumpler John | Hatteras Venture Advisors IV SBIC, LLC | Thorp Clay | Hatteras Venture Partners IV SBIC, LP | INGRAM ROBERT ALEXANDER 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −6,568,527 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | Reed Douglas MD | LEE KENNETH B JR | Crumpler John | Hatteras Venture Advisors IV SBIC, LLC | Thorp Clay | Hatteras Venture Partners IV SBIC, LP | INGRAM ROBERT ALEXANDER 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −2,584,959 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | Reed Douglas MD | LEE KENNETH B JR | Crumpler John | Hatteras Venture Advisors IV SBIC, LLC | Thorp Clay | Hatteras Venture Partners IV SBIC, LP | INGRAM ROBERT ALEXANDER 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −1,009,693 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | ESHELMAN FREDRIC N Director, 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −6,893,224 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | ESHELMAN FREDRIC N Director, 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −2,524,233 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | Strum Jay Officer (Chief Scientific Officer) | 4 | Series 1 Preferred Derivative · Direct | C Conversion of derivative security | −50,000 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | SHAFFER CHRISTY L Director | 4 | Series B Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −172,331 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | SHAFFER CHRISTY L Director | 4 | Series C Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −126,212 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | RUDNICK SETH Director | 4 | Series B Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −8,271 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | MUIR GLENN P Director | 4 | Series C Preferred Stock Derivative · Direct | C Conversion of derivative security | −302,908 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | MedImmune Ventures, Inc. 10% Owner | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −7,142,857 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | MedImmune Ventures, Inc. 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −2,412,628 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | MedImmune Ventures, Inc. 10% Owner | 4 | Series C Preferred Stock Derivative · Direct | C Conversion of derivative security | −673,128 0 owned after | no price filed | 2017-05-24 | |
| 2017-05-22 | Kolchinsky Peter | RA Capital Healthcare Fund LP | RA CAPITAL MANAGEMENT, LLC Other (Fmr 10% Owner See Footnote (2)) | Other (Fmr 10% Owner See Footnote (2)) | Other (Fmr 10% Owner See Footnote (2)) | 4 | Series B Preferred Stock Derivative · Indirect · See footnotes | C Conversion of derivative security | −5,169,916 0 owned after | $1.45 | 2017-05-24 | |
| 2017-05-22 | Kolchinsky Peter | RA Capital Healthcare Fund LP | RA CAPITAL MANAGEMENT, LLC Other (Fmr 10% Owner See Footnote (2)) | Other (Fmr 10% Owner See Footnote (2)) | Other (Fmr 10% Owner See Footnote (2)) | 4 | Series C Preferred Stock Derivative · Indirect · See footnotes | C Conversion of derivative security | −1,682,822 0 owned after | $2.97 | 2017-05-24 | |
| 2017-05-19 holding as of filing | MUIR GLENN P Director | 3/A | Series C Preferred Stock Derivative · Direct | Holding | no price filed | 2017-05-19 | ||
| 2017-05-17 holding as of filing | Eshelman Ventures, LLC | ESHELMAN FREDRIC N 10% Owner | Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | Eshelman Ventures, LLC | ESHELMAN FREDRIC N 10% Owner | Director, 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | MedImmune Ventures, Inc. 10% Owner | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | MedImmune Ventures, Inc. 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | MedImmune Ventures, Inc. 10% Owner | 3 | Series C Preferred Stock Derivative · Direct | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | Thorp Clay 10% Owner | 3 | Series 1 Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | Thorp Clay 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | Thorp Clay 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2017-05-17 | ||
| 2017-05-17 holding as of filing | Thorp Clay 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2017-05-17 | ||
| 2017-05-16 holding as of filing | SHAFFER CHRISTY L Director | 3 | Series B Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2017-05-16 | ||
| 2017-05-16 holding as of filing | SHAFFER CHRISTY L Director | 3 | Series C Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2017-05-16 | ||
| 2017-05-16 holding as of filing | RUDNICK SETH Director | 3 | Series B Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2017-05-16 | ||
| 2017-05-16 holding as of filing | Strum Jay Officer (Chief Scientific Officer) | 3 | Series 1 Preferred Stock Derivative · Direct | Holding | no price filed | 2017-05-16 | ||
| 2017-05-16 holding as of filing | Kolchinsky Peter | RA Capital Healthcare Fund LP | RA CAPITAL MANAGEMENT, LLC 10% Owner | 10% Owner | Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · see footnote | Holding | no price filed | 2017-05-16 | ||
| 2017-05-16 holding as of filing | Kolchinsky Peter | RA Capital Healthcare Fund LP | RA CAPITAL MANAGEMENT, LLC 10% Owner | 10% Owner | Director, 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · see footnote | Holding | no price filed | 2017-05-16 |